RNA Viruses - Coronavirus: New Insights into Mycobacterial Infections

Strategic Insights -

Mycobacterial infections continue to be a significant global public health challenge, with high rates of morbidity and mortality worldwide due to chronic respiratory infections caused by Mycobacteria. According to the World Health Organization (WHO), in 2023, 10.8 million individuals fell ill with Mycobacterium tuberculosis (Mtb), resulting in an estimated 1.25 million deaths. The cases of people affected by nontuberculous mycobacteria (NTM) have risen globally, but the precise incidence and prevalence of both pulmonary and extrapulmonary disease remain unknown.

Key Takeaways:

  • Mycobacterial infections remain a global public health challenge, with high rates of morbidity and mortality worldwide.
  • In 2023, 10.8 million individuals fell ill with Mycobacterium tuberculosis (Mtb), resulting in an estimated 1.25 million deaths.
  • The cases of people affected by nontuberculous mycobacteria (NTM) have risen globally, but the precise incidence and prevalence of both pulmonary and extrapulmonary disease remain unknown.
  • The diagnosis and treatment of mycobacterial infections are challenging and complex, frequently requiring long-duration treatments with several antibiotics, which in most cases leads to poor patient outcomes.
  • Epithelial cells play a crucial role in the early steps of Mycobacteria infections, and human lung organoid technology provides new tools to better understand host-Mycobacteria interactions in the airways and test new therapeutic targets.
  • The World Health Organization (WHO) estimates that 10.8 million individuals fell ill with Mtb in 2023, with 1.25 million deaths resulting from these infections.
  • Nontuberculous mycobacterial pulmonary diseases affect between 0.2 and 2.9 per 100,000 individuals in Europe, mainly patients with cystic fibrosis (CF) and non-CF bronchiectasis.
  • The research, led by Celine Cougoule at the University of Toulouse, highlights the importance of understanding the contribution of epithelial cells in the early steps of Mycobacteria infections and developing new therapeutic targets.

Statistics:

  • 10.8 million individuals fell ill with Mycobacterium tuberculosis (Mtb) in 2023.
  • 1.25 million deaths resulted from Mtb infections in 2023.
  • 0.2 - 2.9 per 100,000 individuals are affected by nontuberculous mycobacterial pulmonary diseases in Europe.
  • 1 in 10 people living in high-endemic countries will have been infected with TB at least once in their lifetime.

Sources:

  • "Lung Organoids As a Human System for Mycobacteria Infection Modeling and Drug Testing." The FEBS Journal, 2025.
  • World Health Organization (WHO). "Global Tuberculosis Report 2023."
  • Association Vaincre la Mucoviscidose. Financial support for the research.
  • University of Toulouse. News release, October 13, 2025.